mitotane has been researched along with cabozantinib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortez, MA; Cote, GJ; Fuentes-Mattei, E; Habra, MA; Hai, T; Hofmann, MC; Jimenez, C; Lee, MH; Ozsari, L; Pagliaro, L; Phan, LM; Sircar, K; Velazquez-Torres, G; Verhaak, R; Wood, CG; Wu, W; Yeung, SC; Zheng, S | 1 |
1 other study(ies) available for mitotane and cabozantinib
| Article | Year |
|---|---|
Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.
Topics: Adenoma; Adrenal Cortex Neoplasms; Adult; Aged; Aged, 80 and over; Anilides; Animals; Antineoplastic Agents; Carcinoma; Cell Division; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitotane; Molecular Targeted Therapy; Neoplasm Proteins; Neovascularization, Pathologic; Proto-Oncogene Proteins c-met; Pyridines; RNA Interference; RNA, Small Interfering; Signal Transduction; Transcriptome; Xenograft Model Antitumor Assays | 2015 |